Get the Stockscreener App
1.405
1.08%
0.015
Ovid Therapeutics Inc stock is traded at $1.405, with a volume of 1.52M.
It is up +1.08% in the last 24 hours and down -23.64% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$1.39
Open:
$1.39
24h Volume:
1.52M
Relative Volume:
0.54
Market Cap:
$99.55M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-1.8733
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
-12.19%
1M Performance:
-23.64%
6M Performance:
+334.18%
1Y Performance:
+23.25%
1-Day Range:
$1.37
$1.42
1-Week Range:
$1.34
$1.63
52-Week Range:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.40 | 98.84M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Visual analytics tools that track Ovid Therapeutics Inc. performance2025 Market Overview & Safe Entry Momentum Stock Tips - newser.com
Can trapped investors hope for a rebound in Ovid Therapeutics Inc.July 2025 Summary & Fast Momentum Entry Tips - newser.com
Visual trend scoring systems applied to Ovid Therapeutics Inc.Insider Selling & Technical Pattern Based Buy Signals - newser.com
How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsJuly 2025 Intraday Action & AI Driven Stock Movement Reports - newser.com
Using flow based indicators on Ovid Therapeutics Inc.Trade Entry Report & Verified Swing Trading Watchlist - newser.com
What MACD trends signal for Ovid Therapeutics Inc. (1OT) stockJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
What analysts say about Ovid Therapeutics Inc 1OT stockSector Leadership Analysis & Low Risk Capital Appreciation - earlytimes.in
Combining machine learning predictions for Ovid Therapeutics Inc.Watch List & Technical Buy Zone Confirmation - newser.com
Is Ovid Therapeutics Inc. stock a safe haven assetWeekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.July 2025 Spike Watch & Real-Time Volume Spike Alerts - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflation2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
How strong is Ovid Therapeutics Inc. stock balance sheetJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Short Interest in Ovid Therapeutics (NASDAQ:OVID) Grows By 463.2% - MarketBeat
Ovid Therapeutics (OVID) Price Target Increased by 22.06% to 4.23 - Nasdaq
Quarterly Recap: How Ovid Therapeutics Inc. stock compares to industry benchmarksEarnings Summary Report & Weekly Sector Rotation Insights - fcp.pa.gov.br
OVID PRE 14A: approvals for Series B conversion and warrants - Stock Titan
OVID special meeting to approve PIPE share issuances and 315M authorization - Stock Titan
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ovid Therapeutics Inc Stock (OVID) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):